Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Bhalla

Showing results (111-120 of 189) with videos related to

Pageof 19
Sort By:
Molecular Cancer Therapeutics|July 24, 2014
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITDWarren Fiskus, Sunil Sharma, Jun Qi, et al.
Molecular Cancer Therapeutics|February 28, 2012
Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cellsRekha Rao, Ramesh Balusu, Warren Fiskus, et al.
Molecular Cancer Therapeutics|July 29, 2010
Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cellsRekha Rao, Srilatha Nalluri, Warren Fiskus, et al.
The Journal of Biological Chemistry|March 7, 2009
p53 acetylation is crucial for its transcription-independent proapoptotic functionsHirohito Yamaguchi, Nicholas T Woods, Landon G Piluso, et al.
Pharmacotherapy|June 26, 2013
Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemiaCasey B Williams, Suman Kambhampati, Warren Fiskus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2020
Editor's Note: Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-mediated Potentiation of Bortezomib-induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma CellsRekha Rao, Srilatha Nalluri, Warren Fiskus, et al.
Molecular Cancer Therapeutics|April 8, 2010
Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cellsRekha Rao, Srilatha Nalluri, Ravindra Kolhe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2010
Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cellsRekha Rao, Srilatha Nalluri, Warren Fiskus, et al.
Cancer Biology & Therapy|March 13, 2009
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cellsWarren Fiskus, Kate Buckley, Rekha Rao, et al.
British Journal of Haematology|August 12, 2009
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin LymphomaMichael Dickinson, David Ritchie, Daniel J DeAngelo, et al.
Pageof 19

Showing results (111-120 of 189) with videos related to

Sort By:
Pageof 19
Molecular Cancer Therapeutics|July 24, 2014
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITDWarren Fiskus, Sunil Sharma, Jun Qi, et al.
Molecular Cancer Therapeutics|February 28, 2012
Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cellsRekha Rao, Ramesh Balusu, Warren Fiskus, et al.
Molecular Cancer Therapeutics|July 29, 2010
Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cellsRekha Rao, Srilatha Nalluri, Warren Fiskus, et al.
The Journal of Biological Chemistry|March 7, 2009
p53 acetylation is crucial for its transcription-independent proapoptotic functionsHirohito Yamaguchi, Nicholas T Woods, Landon G Piluso, et al.
Pharmacotherapy|June 26, 2013
Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemiaCasey B Williams, Suman Kambhampati, Warren Fiskus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2020
Editor's Note: Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-mediated Potentiation of Bortezomib-induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma CellsRekha Rao, Srilatha Nalluri, Warren Fiskus, et al.
Molecular Cancer Therapeutics|April 8, 2010
Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cellsRekha Rao, Srilatha Nalluri, Ravindra Kolhe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2010
Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cellsRekha Rao, Srilatha Nalluri, Warren Fiskus, et al.
Cancer Biology & Therapy|March 13, 2009
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cellsWarren Fiskus, Kate Buckley, Rekha Rao, et al.
British Journal of Haematology|August 12, 2009
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin LymphomaMichael Dickinson, David Ritchie, Daniel J DeAngelo, et al.
Pageof 19